Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 26, 2023
Discovery & Translation
Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID vaccine and more
BioCentury’s roundup of translational news
BioCentury | Jan 28, 2022
Emerging Company Profile
TenSixteen: Targeting dynamic genome to find driver mutations, catch cancer earlier
Foresite, GV lead $40M A round to build data platform, Dx assay
BioCentury | Nov 30, 2018
Targets & Mechanisms
Revving up metabolism at ASH 2018
A dive into the ASH 2018 abstracts highlights cancer metabolism as a top focus
BioCentury | Nov 2, 2018
Targets & Mechanisms
FDA’s pediatric target picks
FDA looks beyond company pipeline horizons for pediatric oncology targets
BioCentury | Jun 22, 2018
Targets & Mechanisms
T cell balancing act
The latest debate in CAR T is whether CD8+ or CD4+ cells play the bigger role
BioCentury | Dec 8, 2017
Targets & Mechanisms
Epiphenomena at ASH
Epigenetics and cell therapies are preclinical hotspots at ASH 2017
Items per page:
1 - 9 of 9